Premium
Gene therapy for posterior uveitis
Author(s) -
DICK AD
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.3466.x
Subject(s) - uveitis , retina , inflammation , macrophage , immunology , medicine , genetic enhancement , ophthalmology , pathology , gene , biology , neuroscience , in vitro , genetics
Purpose To investigate the role of gene therapy incorporating release of immunomodulatory cytokines in animal models of intraocular inflammation Methods By inoculating with either AAV or lente viruses incorporating genes for IL‐1RA or IL‐10 into either the anterior chamber or subretinally we onserved the ability to suppress either endotoxin induced uveitis (EIU) or experimental autoimmiune uveoretinitis (EAU). Results Anterior chamber inoculation with lente‐IL‐10 or IL‐1RA successfully suppresses inflammation and protein exudation into the eye during the course of EIU. Subretinal injection of AAV‐IL‐10 suppresses EAU. The extent of local macrophage activation is also suppressed as there is marked reduction in nitrotyrosine expression within the retina. Conclusion Gene therapy with immunomodulatory cytokines offers a potential to suppress active inflammatory processes within the retina. Mechanisms will be discussed in the talk in relation to macrophage activation and restoring myeloid cell (microgolial) homeostasis within the retina.